"We're calling upon urologists and primary care physicians to start the conversation and normalize discussion about erectile dysfunction with their patients before they fall through the cracks and ended up victims of these predatory online services," says Jack Vercnocke, MD.
"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
"The main thing that we were surprised by was that at this point in time, ChatGPT couldn't give us consistent results," says Athena Barrett.
"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.
Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.
Join David Albala, MD, as he explores the use of advanced imaging techniques in prostate cancer diagnosis and management, highlighting PSMA-PET scans and their pivotal role in modern prostate cancer care.
“When you're talking about Medicare patients who are on multiple medications, and this is not the only thing that they're taking, to pay over $100 for 1 medication is sometimes not possible,” says Katherine Shapiro, MD.
“Company 3 was the most surprising; the cost was $5220 per year for 10 20-mg [tadalafil] pills per month,” says Jack Vercnocke, MD.
"It's really a monumental change for patients, and it is a massive win for our health care system," says Benjamin Pockros, MD.
Dr. Amir H. Lebastchi elaborates on his approach to integrating MRI and ultrasound fusion-based technology for guiding treatment selection and tailoring therapy for patients with prostate cancer.
Amir H. Lebastchi, MD, outlines his general strategy for active surveillance in prostate cancer patients, emphasizing the role of MRI and fusion-guided prostate biopsy.
“We also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC,” says Nirmish Singla, MD, MSc.
Alexandra Sokolova, MD, explains the importance of genetic testing for patients with high-risk localized and advanced prostate cancer, as well as for their high-risk family members.
“Our aim overall is to describe Medicare Part D prescription drug coverage and use of prior authorization and step therapy for these medications,” says Katherine Shapiro, MD.
"We really have to think beyond just the individual health impact to understand what's underlying these disparities," says Raveen Syan, MD, FPMRS.
“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.
An overview of patient monitoring strategies experts use to establish individualized followup with patients receiving therapy for OAB in the third-line setting.
Focused discussion on effectively communicating expectations for third-line therapies with patients being treated for OAB.
“We looked at the costs of various quantities and strengths of sildenafil citrate [Viagra] and tadalafil [Cialis] from 3 three well-known direct-to-consumer online pharmacies, and we compared them to Cost Plus Drugs, an online pharmacy known for its competitive wholesale pricing,” says Jack Vercnocke, MD.
"It's not just teaching all about prostate cancer; it's real life and how people are experiencing prostate cancer," says David F. Mobley, MD.
"Although there may be some variety in prevalence and severity of disease, what's most striking is when we know a patient has that diagnosis, we have consistently found that minority women are less likely to receive treatments for overactive bladder," says Raveen Syan, MD, FPRMS.
"This is a whole other approach to treating patients with this cancer. If you think about that from the perspective of prostate cancer as a whole, this is a big deal," says Thomas A. Hope, MD.
Dr. Amir H. Lebastchi reviews retrospective data comparing software-based and cognitive-based fusion biopsy approaches, providing valuable insights into the findings.
Amir H. Lebastchi, MD, explores the evolving landscape in the context of fusion-guided prostate biopsy methods.
“The goal of our work, essentially, was to leverage a national population-based cancer registry to comprehensively analyze multiple socioeconomic determinants of racial disparities and survival outcomes among nearly 400,000 patients with renal cell carcinoma,” says Nirmish Singla, MD, MSc.
"We had very high specificities. The specificities amongst the 3 readers ranged from 92% to 96%," says Phillip H. Kuo, MD, PhD, FACR.
